Genmab — Januar 2020
-
Hvad er status mht at nå 3mia i 2019?
-
-
-
Horizon also note in their presentation a new Development Program Evaluating Diffuse Cutaneous Scleroderma
for Teprotumumab
https://ir.horizontherapeutics.com/static-files/5de49a13-4b11-49d6-9f8b-fb680f82cabb -
New small Usmani trial- Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma https://www.clinicaltrials.gov/ct2/show/NCT04230031?cond=Multiple+Myeloma&sfpd_s=01%2F02%2F2020&sfpd_d=14&sel_rss=new14
-
and a new trial by the Mayo Clinic- Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study https://www.clinicaltrials.gov/ct2/show/NCT04230304?cond=Chronic+Lymphocytic+Leukemia&sfpd_s=01%2F02%2F2020&sfpd_d=14&sel_rss=new14
-
thx E L. Now we have 3 studies in dara + ibrutinib in CLL. https://www.clinicaltrials.gov/ct2/results?cond=&term=daratumumab+cll&cntry=&state=&city=&dist=
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind